For research use only, not for therapeutic use.
NCC007（Cat No.:I018957）is an investigational compound known for its potential therapeutic applications in oncology and autoimmune diseases. As a selective inhibitor of specific protein kinases, NCC007 modulates critical signaling pathways involved in cell proliferation and immune responses. Preclinical studies indicate its efficacy in inhibiting tumor growth and enhancing anti-tumor immunity. Additionally, NCC007 shows promise in managing chronic inflammatory conditions by regulating immune cell activity. Ongoing research aims to further elucidate its mechanisms of action and to assess its safety and effectiveness in clinical trials, paving the way for future therapeutic options.
| Catalog Number | I018957 |
| CAS Number | 2342583-66-6 |
| Molecular Formula | C₂₂H₂₈F₃N₇ |
| Purity | ≥95% |
| IUPAC Name | 9-(1-cyclopropylethyl)-2-N-[2-(dimethylamino)ethyl]-6-N-[[3-(trifluoromethyl)phenyl]methyl]purine-2,6-diamine |
| InChI | InChI=1S/C22H28F3N7/c1-14(16-7-8-16)32-13-28-18-19(29-21(30-20(18)32)26-9-10-31(2)3)27-12-15-5-4-6-17(11-15)22(23,24)25/h4-6,11,13-14,16H,7-10,12H2,1-3H3,(H2,26,27,29,30) |
| InChIKey | GHRNSZVMIARHIS-UHFFFAOYSA-N |
| SMILES | CC(C1CC1)N2C=NC3=C(N=C(N=C32)NCCN(C)C)NCC4=CC(=CC=C4)C(F)(F)F |
| Reference | [1]. Lee JW, et al. Chemical Control of Mammalian Circadian Behavior through Dual Inhibition of Casein Kinase Iα and δ. J Med Chem. 2019 Feb 28;62(4):1989-1998. |
